8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 24, 2026·SEC
CAMP4 Therapeutics Corporation(CAMP)Earnings, Financials & Key Ratios
CAMP•NASDAQ
Price updated Jun 17, 2026
AboutCAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.Show more
- Revenue$3M+436.5%
- EBITDA-$50M+1.9%
- Net Income-$80M-55.2%
- EPS (Diluted)-2.65+0.4%
- Gross Margin53.14%-46.9%
- EBITDA Margin-1441.45%+81.7%
- Operating Margin-1488.31%+81.7%
- Net Margin-2298.54%+71.1%
- ROE-145.07%-76.9%
CAMP Key Insights
CAMP4 Therapeutics Corporation (CAMP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 30.6% over 5 years
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Sales declining 59.2% over 5 years
- ✗Shares diluted 55.8% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CAMP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CAMP Price & Volume
CAMP4 Therapeutics Corporation (CAMP) stock price & volume — 10-year historical chart
Loading chart...
CAMP Growth Metrics
CAMP4 Therapeutics Corporation (CAMP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-35.5%
5 Years-59.18%
3 Years-
TTM160.53%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-66.69%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM19.22%
Return on Capital
10 Years-25.07%
5 Years-50.58%
3 Years-75.25%
Last Year-60.89%
CAMP Recent Earnings
CAMP4 Therapeutics Corporation (CAMP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 5/12 qtrs (63%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.32-52.4%
$0.21
Rev
$1M+15.7%
$1M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.87-180.6%
$0.31
Rev
$300,000-36.9%
$475,200
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.55-17.0%
$0.47
Rev
$795,000+83.5%
$433,333
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.62+7.5%
$0.67
Rev
$1M+1069.5%
$128,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.32vs $0.21-52.4% | $1Mvs $1M+15.7% |
| Q2 2026 | Mar 5, 2026 | $0.87vs $0.31-180.6% | $300,000vs $475,200-36.9% |
| Q4 2025 | Nov 6, 2025 | $0.55vs $0.47-17.0% | $795,000vs $433,333+83.5% |
| Q3 2025 | Aug 14, 2025 | $0.62vs $0.67+7.5% | $1Mvs $128,000+1069.5% |
Based on last 12 quarters of dataView full earnings history →
CAMP Peer Comparison
CAMP4 Therapeutics Corporation (CAMP) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.65B | 26.91 | -4.62 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.7B | 21.60 | 9.43 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 6.51B | 78.53 | 10.09 | 114.51% | -22.58% | |||
 KRYS | 10.07B | 341.66 | 49.95 | 33.94% | 53.92% | 19.25% | 0.01 | |
 BEAM | 3.34B | 32.48 | -40.10 | 120.01% | -49.17% | -5.89% | 0.24 | |
 ARWR | 11.42B | 81.04 | -6642.62 | 232.58% | -48.38% | -55.09% | 0.73 | |
 NTLA | 1.71B | 15.20 | -3.99 | 16.92% | -5.97% | -57.27% | 0.14 |
Compare CAMP vs Peers
CAMP4 Therapeutics Corporation (CAMP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CAMP Income Statement
CAMP4 Therapeutics Corporation (CAMP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Feb'18 | Feb'19 | Feb'20 | Feb'21 | Feb'22 | Feb'23 | Nov'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 365.91M | 363.8M | 366.11M | 308.59M | 295.84M | 0 | 350K | 652K | 3.5M | 3.93M |
Revenue Growth % | 4.22% | -0.58% | 0.63% | -15.71% | -4.13% | -100% | - | 86.29% | 436.5% | 160.53% |
Cost of Goods Sold | 215.02M | 216.04M | 222.8M | 186.18M | 173.95M | 0 | 0 | 0 | 1.64M | 936K |
COGS % of Revenue | 58.76% | 59.38% | 60.86% | 60.33% | 58.8% | - | - | - | 46.86% | - |
Gross Profit | 150.89M▲ 0% | 147.76M▼ 2.1% | 143.3M▼ 3.0% | 122.41M▼ 14.6% | 121.89M▼ 0.4% | 0▼ 100.0% | 350K▲ 0% | 652K▲ 86.3% | 1.86M▲ 185.1% | 3M▲ 0% |
Gross Margin % | 41.24% | 40.62% | 39.14% | 39.67% | 41.2% | - | 100% | 100% | 53.14% | 76.21% |
Gross Profit Growth % | 5.26% | -2.07% | -3.02% | -14.58% | -0.42% | -100% | - | 86.29% | 185.12% | - |
Operating Expenses | 142.94M | 120.05M | 159.96M | 125.87M | 134.76M | 45M | 52.23M | 53.74M | 53.92M | 55.03M |
OpEx % of Revenue | 39.06% | 33% | 43.69% | 40.79% | 45.55% | - | 14922.57% | 8242.33% | 1541.45% | - |
Selling, General & Admin | 102.19M | 80.96M | 118.2M | 95.28M | 100.9M | 10.23M | 11.61M | 14.92M | 17.36M | 17.75M |
SG&A % of Revenue | 27.93% | 22.25% | 32.29% | 30.88% | 34.11% | - | 3318% | 2288.8% | 496.2% | - |
Research & Development | 25.76M | 27.66M | 29.44M | 25.81M | 28.44M | 34.77M | 40.62M | 38.82M | 38.2M | 37.7M |
R&D % of Revenue | 7.04% | 7.6% | 8.04% | 8.36% | 9.61% | - | 11604.57% | 5953.53% | 1092.11% | - |
Other Operating Expenses | 445K | -672K | 12.32M | 4.78M | 5.42M | 0 | 0 | 0 | -1.64M | -416K |
Operating Income | 7.96M▲ 0% | 19.7M▲ 147.6% | -16.77M▼ 185.1% | -3.87M▲ 76.9% | -15.31M▼ 295.8% | -45M▼ 193.9% | -51.88M▼ 15.3% | -53.09M▼ 2.3% | -52.06M▲ 1.9% | -52.03M▲ 0% |
Operating Margin % | 2.17% | 5.41% | -4.58% | -1.25% | -5.18% | - | -14822.57% | -8142.33% | -1488.31% | -1322.62% |
Operating Income Growth % | 493.21% | 147.58% | -185.15% | 76.93% | -295.79% | -193.87% | -15.28% | -2.33% | 1.93% | - |
EBITDA | 30.91M | 39.71M | 15.22M | 18.13M | 7.49M | -44.12M | -50.2M | -51.39M | -50.42M | -50.29M |
EBITDA Margin % | 8.45% | 10.92% | 4.16% | 5.88% | 2.53% | - | -14343.14% | -7882.21% | -1441.45% | -1278.44% |
EBITDA Growth % | 24.59% | 28.46% | -61.68% | 19.16% | -58.69% | -689.01% | -13.78% | -2.37% | 1.89% | 2.59% |
D&A (Non-Cash Add-back) | 22.96M | 20.02M | 31.99M | 22M | 22.8M | 878K | 1.68M | 1.7M | 1.64M | 1.74M |
EBIT | 0 | 0 | -16.77M | -3.87M | -15.31M | -45M | -51.88M | -53.09M | -52.06M | -53.97M |
Net Interest Income | -10.28M | -16.73M | -20.1M | -15.49M | -15.32M | -6.26M | 2.81M | 1.33M | 2.17M | 2.5M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 2.81M | 1.33M | 2.17M | 2.5M |
Interest Expense | 10.28M | 16.73M | 20.1M | 15.49M | 15.32M | 6.26M | 0 | 0 | 0 | 0 |
Other Income/Expense | 31.03M | 12.87M | -41.55M | -16.73M | -14.75M | 809K | 2.59M | 1.3M | -28.34M | -34.27M |
Pretax Income | 28.71M▲ 0% | 23.86M▼ 16.9% | -58.32M▼ 344.5% | -20.6M▲ 64.7% | -30.06M▼ 46.0% | -44.19M▼ 47.0% | -49.29M▼ 11.5% | -51.79M▼ 5.1% | -80.4M▼ 55.2% | -86.3M▲ 0% |
Pretax Margin % | 7.85% | 6.56% | -15.93% | -6.67% | -10.16% | - | -14083.14% | -7943.4% | -2298.54% | -2193.72% |
Income Tax | 10.68M | -1.33M | 20.45M | 561K | 1.09M | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 37.2% | -5.58% | -35.07% | -2.72% | -3.62% | 0% | 0% | 0% | 0% | 0% |
Net Income | 16.62M▲ 0% | 18.4M▲ 10.7% | -78.77M▼ 528.2% | -21.16M▲ 73.1% | -31.15M▼ 47.2% | -44.19M▼ 41.9% | -49.29M▼ 11.5% | -51.79M▼ 5.1% | -80.4M▼ 55.2% | -86.3M▲ 0% |
Net Margin % | 4.54% | 5.06% | -21.52% | -6.86% | -10.53% | - | -14083.14% | -7943.4% | -2298.54% | -2193.72% |
Net Income Growth % | 332.37% | 10.72% | -528.17% | 73.14% | -47.22% | -41.88% | -11.54% | -5.07% | -55.25% | -66.69% |
Net Income (Continuing) | - | - | -78.77M | -21.16M | -31.15M | -44.19M | -49.29M | -51.79M | -80.4M | -86.3M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.46▲ 0% | 0.52▲ 13.0% | -2.34▼ 550.0% | -0.62▲ 73.5% | -0.88▼ 41.9% | -0.90▼ 2.3% | -4.07▼ 352.2% | -2.66▲ 34.6% | -2.65▲ 0.4% | -1.49▲ 0% |
EPS Growth % | 330% | 13.04% | -550% | 73.5% | -41.94% | -2.27% | -352.22% | 34.64% | 0.38% | 19.22% |
EPS (Basic) | 0.47 | 0.53 | -2.35 | -0.62 | -0.88 | -0.90 | -4.07 | -2.66 | -2.65 | - |
Diluted Shares Outstanding | 36.14M | 35.29M | 33.67M | 34.39M | 35.25M | 36.13M | 12.12M | 19.51M | 30.38M | 57.92M |
Basic Shares Outstanding | 35.25M | 34.59M | 33.48M | 34.12M | 35.25M | 36.1M | 12.12M | 19.51M | 30.38M | 57.92M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CAMP Balance Sheet
CAMP4 Therapeutics Corporation (CAMP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Feb'18 | Feb'19 | Feb'20 | Feb'21 | Feb'22 | Feb'23 | Nov'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 275.88M | 403.5M | 237.87M | 215.23M | 193.59M | 84.41M | 40.01M | 66.38M | 114.09M | 102.2M |
Cash & Short-Term Investments | 156M | 274.01M | 107.4M | 91.69M | 91.11M | 83.19M | 38.38M | 64.04M | 109.52M | 99.21M |
Cash Only | 132.6M | 256.5M | 107.4M | 91.69M | 91.11M | 83.19M | 38.38M | 64.04M | 109.52M | 99.21M |
Short-Term Investments | 23.4M | 17.51M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 71.58M | 78.08M | 72.27M | 67.85M | 58.59M | 678K | 442K | 108K | 155K | 0 |
Days Sales Outstanding | 71.4 | 78.34 | 72.05 | 80.26 | 72.29 | - | 460.94 | 60.46 | 16.17 | 8.51 |
Inventory | 36.3M | 32.03M | 36.78M | 32.16M | 20.18M | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 61.62 | 54.12 | 60.25 | 63.05 | 42.34 | - | - | - | - | - |
Other Current Assets | 12M | 19.37M | 21.41M | 23.52M | 23.7M | 205K | 245K | 211K | 4.42M | 2.99M |
Total Non-Current Assets | 197.11M | 200.13M | 257.94M | 226.6M | 208.7M | 18.14M | 14.93M | 11.92M | 3.71M | 3.26M |
Property, Plant & Equipment | 21.26M | 27.02M | 76.5M | 62.23M | 50.06M | 16.8M | 13.31M | 10.3M | 2.74M | 2.29M |
Fixed Asset Turnover | 17.21x | 13.46x | 4.79x | 4.96x | 5.91x | - | 0.03x | 0.06x | 1.28x | 0.71x |
Goodwill | 72.98M | 80.81M | 106.33M | 94.47M | 94M | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 52.46M | 47.16M | 45.9M | 38.94M | 33.01M | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 8.84M | 4.91M | 0 | 24.16M | 24.34M | 0 | 0 | 0 | 894K | 2.52M |
Other Non-Current Assets | 9.99M | 17.6M | 24.77M | 2.36M | 3.05M | 1.35M | 1.62M | 1.62M | 83K | 970K |
Total Assets | 472.99M▲ 0% | 603.63M▲ 27.6% | 495.81M▼ 17.9% | 441.82M▼ 10.9% | 402.29M▼ 8.9% | 102.55M▼ 74.5% | 54.95M▼ 46.4% | 78.31M▲ 42.5% | 117.81M▲ 50.4% | 105.46M▲ 0% |
Asset Turnover | 0.77x | 0.60x | 0.74x | 0.70x | 0.74x | - | 0.01x | 0.01x | 0.03x | 0.04x |
Asset Growth % | 16.02% | 27.62% | -17.86% | -10.89% | -8.95% | -74.51% | -46.42% | 42.52% | 50.44% | 494.07% |
Total Current Liabilities | 95.53M | 83.59M | 121.47M | 107.38M | 94.88M | 7.95M | 7.81M | 9.6M | 15.51M | 16.62M |
Accounts Payable | 35.48M | 39.9M | 28.45M | 36.83M | 30.78M | 2.15M | 1.04M | 1.21M | 182K | 863K |
Days Payables Outstanding | 60.22 | 67.41 | 46.61 | 72.21 | 64.58 | - | - | - | 40.53 | 334.88 |
Short-Term Debt | 32.22M | 36.84M | 37.78M | 10.94M | 7.74M | 0 | 0 | 0 | 286K | 384K |
Deferred Revenue (Current) | 17.76M | 24.26M | 34.7M | 38.93M | 32.4M | 0 | 0 | 385K | 9.39M | 20.46M |
Other Current Liabilities | 45.55M | 22.48M | 20.3M | 20.68M | 23.96M | 1.78M | 2.34M | 3.2M | 5.66M | 4.3M |
Current Ratio | 2.89x | 4.83x | 1.96x | 2.00x | 2.04x | 10.62x | 5.13x | 6.92x | 7.35x | 6.15x |
Quick Ratio | 2.51x | 4.44x | 1.66x | 1.70x | 1.83x | 10.62x | 5.13x | 6.92x | 7.35x | 6.15x |
Cash Conversion Cycle | 72.8 | 65.05 | 85.7 | 71.1 | 50.04 | - | - | - | - | -326.36 |
Total Non-Current Liabilities | 178.55M | 314.38M | 236.41M | 235.12M | 227.23M | 172.13M | 170.87M | 5.57M | 54.59M | 57.93M |
Long-Term Debt | 154.3M | 275.9M | 201.37M | 199.86M | 201.43M | 0 | 0 | 0 | 1.69M | 1.74M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 10.03M | 8.63M | 5.56M | 0 | 8.73M |
Deferred Tax Liabilities | -16.76M | 963K | 122K | 6.96M | 208K | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 24.25M | 38.48M | 7.47M | 4.08M | 11.1M | 162.11M | 162.23M | 2K | 44.79M | 56.19M |
Total Liabilities | 274.08M | 397.97M | 357.89M | 342.5M | 322.11M | 180.08M | 178.68M | 15.16M | 70.1M | 74.56M |
Total Debt | 154.3M | 275.9M | 234.49M | 210.8M | 209.17M | 12.39M | 11.69M | 8.65M | 1.97M | 2.12M |
Net Debt | 21.7M | 19.41M | 127.08M | 119.11M | 118.05M | -70.8M | -26.69M | -55.39M | -107.54M | -97.09M |
Debt / Equity | 0.78x | 1.34x | 1.70x | 2.12x | 2.61x | - | - | 0.14x | 0.04x | 0.07x |
Debt / EBITDA | 4.99x | 6.95x | 15.41x | 11.63x | 27.92x | - | - | - | - | -0.04x |
Net Debt / EBITDA | 0.70x | 0.49x | 8.35x | 6.57x | 15.76x | - | - | - | - | 1.93x |
Interest Coverage | 0.77x | 1.18x | -0.83x | -0.25x | -1.00x | -7.19x | - | - | - | - |
Total Equity | 198.92M▲ 0% | 205.65M▲ 3.4% | 137.92M▼ 32.9% | 99.32M▼ 28.0% | 80.18M▼ 19.3% | -77.53M▼ 196.7% | -123.73M▼ 59.6% | 63.14M▲ 151.0% | 47.7M▼ 24.5% | 30.9M▲ 0% |
Equity Growth % | 21.29% | 3.39% | -32.94% | -27.99% | -19.27% | -196.69% | -59.59% | 151.03% | -24.45% | 199.55% |
Book Value per Share | 5.50 | 5.83 | 4.10 | 2.89 | 2.27 | -2.15 | -10.20 | 3.24 | 1.57 | 0.53 |
Total Shareholders' Equity | 198.92M | 205.65M | 137.92M | 99.32M | 80.18M | -77.53M | -123.73M | 63.14M | 47.7M | 30.9M |
Common Stock | 357K | 336K | 343K | 350K | 359K | 1K | 1K | 2K | 6K | 6K |
Retained Earnings | -19.46M | -2.23M | -81.53M | -129.25M | -156.78M | -110.67M | -159.96M | -211.75M | -292.16M | -310.49M |
Treasury Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
Accumulated OCI | -199K | -661K | -1.38M | -1.11M | -2.44M | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CAMP Cash Flow Statement
CAMP4 Therapeutics Corporation (CAMP) cash flow — operating, investing & free cash flow history
| Metric | Feb'18 | Feb'19 | Feb'20 | Feb'21 | Feb'22 | Feb'23 | Nov'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 66.89M | 47.74M | 11.54M | 28.59M | -4.22M | -38.54M | -44.16M | -45.56M | -29.55M | -26.25M |
Operating CF Margin % | 18.28% | 13.12% | 3.15% | 9.26% | -1.43% | - | -12615.71% | -6988.04% | -844.85% | - |
Operating CF Growth % | 159.32% | -28.63% | -75.82% | 147.62% | -114.76% | -813.77% | -14.56% | -3.19% | 35.14% | 186.19% |
Net Income | 16.62M | 18.4M | -79.3M | -56.31M | -27.99M | -44.19M | -49.29M | -51.79M | -80.4M | -86.3M |
Depreciation & Amortization | 22.96M | 9.79M | 23.31M | 22M | 22.8M | 878K | 1.68M | 1.7M | 1.64M | 1.74M |
Stock-Based Compensation | 9.3M | 9.54M | 10.67M | 11.36M | 11.32M | 1.38M | 2.91M | 4.03M | 4M | 3.14M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 27.79M | 34.75M | 53.13M | 40.56M | -11.94M | 3.02M | 705K | 2.38M | 32.2M | 39.12M |
Working Capital Changes | -9.77M | -24.74M | 3.74M | 10.96M | 1.59M | 373K | -154K | -1.88M | 13.01M | 16.05M |
Change in Receivables | -6.45M | -4.02M | 7.55M | 1.62M | 1.44M | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | -6.52M | 5.04M | -1.44M | 8.69M | 5.16M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.03M | -421K |
Cash from Investing | -26.45M | -21.79M | -65.7M | -13.69M | -7.58M | -4.03M | -678K | -441K | -243K | -243K |
Capital Expenditures | -8.34M | -10.4M | -21.3M | -11.36M | -13.3M | -4.03M | -678K | -441K | -279K | -243K |
CapEx % of Revenue | 2.28% | 2.86% | 5.82% | 3.68% | 4.5% | - | 193.71% | 67.64% | 7.98% | 6.18% |
Acquisitions | 0 | -13.03M | -60.65M | 0 | 0 | 0 | 0 | 0 | 36K | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -18.11M | 1.65M | 16.25M | -2.34M | 5.72M | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | -2.26M | 98.5M | -94.82M | -27.32M | -2.64M | 100.16M | 301K | 71.66M | 75.89M | 76.1M |
Debt Issued (Net) | - | - | - | - | - | -93K | 116K | -824K | -208K | 40K |
Equity Issued (Net) | - | - | - | - | - | 0 | 0 | 0 | 61.17M | 61.22M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -49M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -2.26M | 98.5M | -94.82M | -27.32M | -2.64M | 100.25M | 185K | 72.49M | 14.93M | 14.84M |
Net Change in Cash | 38.9M▲ 0% | 123.9M▲ 218.5% | -149.1M▼ 220.3% | -12.78M▲ 91.4% | -15.4M▼ 20.5% | 83.19M▲ 640.1% | -44.53M▼ 153.5% | 25.66M▲ 157.6% | 46.09M▲ 79.6% | 49.61M▲ 0% |
Free Cash Flow | 58.55M▲ 0% | 37.34M▼ 36.2% | -9.76M▼ 126.1% | 17.23M▲ 276.6% | -17.52M▼ 201.7% | -42.57M▼ 143.0% | -44.83M▼ 5.3% | -46M▼ 2.6% | -29.83M▲ 35.2% | -26.25M▲ 0% |
FCF Margin % | 16% | 10.26% | -2.67% | 5.58% | -5.92% | - | -12809.43% | -7055.67% | -852.83% | -667.21% |
FCF Growth % | 228.33% | -36.23% | -126.13% | 276.58% | -201.67% | -143.02% | -5.32% | -2.61% | 35.15% | 46.88% |
FCF per Share | 1.62 | 1.06 | -0.29 | 0.50 | -0.50 | -1.18 | -3.70 | -2.36 | -0.98 | -0.45 |
FCF Conversion (FCF/Net Income) | 4.03x | 2.59x | -0.15x | -1.35x | 0.14x | 0.87x | 0.90x | 0.88x | 0.37x | 0.30x |
Interest Paid | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
Taxes Paid | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
CAMP Key Ratios
CAMP4 Therapeutics Corporation (CAMP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 9.16% | 9.1% | -45.86% | -17.84% | -34.71% | -3335.25% | - | -82.02% | -145.07% | -194.74% |
Return on Invested Capital (ROIC) | 2.73% | 6.63% | -5.13% | -1.2% | -5.51% | -135.25% | - | - | - | 124.72% |
Gross Margin | 41.24% | 40.62% | 39.14% | 39.67% | 41.2% | - | 100% | 100% | 53.14% | 76.21% |
Net Margin | 4.54% | 5.06% | -21.52% | -6.86% | -10.53% | - | -14083.14% | -7943.4% | -2298.54% | -2193.72% |
Debt / Equity | 0.78x | 1.34x | 1.70x | 2.12x | 2.61x | - | - | 0.14x | 0.04x | 0.07x |
Interest Coverage | 0.77x | 1.18x | -0.83x | -0.25x | -1.00x | -7.19x | - | - | - | - |
FCF Conversion | 4.03x | 2.59x | -0.15x | -1.35x | 0.14x | 0.87x | 0.90x | 0.88x | 0.37x | 0.30x |
Revenue Growth | 4.22% | -0.58% | 0.63% | -15.71% | -4.13% | -100% | - | 86.29% | 436.5% | 160.53% |
Related:CAMP Dividend History·CAMP Revenue History·CAMP Price History·CAMP P/E History·CAMP Financial Ratios·CAMP Institutional Holders
CAMP SEC Filings & Documents
CAMP4 Therapeutics Corporation (CAMP) SEC filings — annual & quarterly reports (10-K, 10-Q)
CAMP Frequently Asked Questions
CAMP4 Therapeutics Corporation (CAMP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CAMP4 Therapeutics Corporation (CAMP) reported $3.9M in revenue for fiscal year 2025. This represents a 92% decrease from $49.3M in 1996.
CAMP4 Therapeutics Corporation (CAMP) grew revenue by 436.5% over the past year. This is strong growth.
CAMP4 Therapeutics Corporation (CAMP) reported a net loss of $86.3M for fiscal year 2025.
Dividend & Returns
CAMP4 Therapeutics Corporation (CAMP) has a return on equity (ROE) of -145.1%. Negative ROE indicates the company is unprofitable.
CAMP4 Therapeutics Corporation (CAMP) had negative free cash flow of $26.2M in fiscal year 2025, likely due to heavy capital investments.